Incyte Corporation

ISIN US45337C1027 Symbol INCY Industry Biotechnology Sector Healthcare
Incyte Price
86.16USD 1.21%
1y Low: 69.2
1y High: 110.4
1y Low: 69.2
1y High: 110.4
Incyte Analyst Rating
Strong Buy
Strong Sell
Market Cap
17.5 B USD
Dividend Yield
Performance 1y
19.65 %

Incyte Stock Chart

Incyte Dividend Chart

Incyte Dividend Calendar

Year # Div. Div. Paid Div. Yield Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Incyte Performance

1 Week
1.39 %
1 Month
2.96 %
6 Months
1.40 %
Year to Date
1.53 %
1 Year
19.65 %
5 Years
17.52 %

Incyte Revenue, EBIT, and Income

Incyte Margins

Incyte Shares Outstanding

Useful Links

Search Twitter: $INCY, #INCY

Incyte Company Info

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. Further, it is involved in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; MorphoSys AG; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

Incyte Price to Earnings Ratio (PE Ratio): 47.6

The current Price to Earnings Ratio of Incyte is 47.6.
The PE Ratio is calcluated by dividing the current Incyte share price (86.16 USD) by the earnings per share (1.9).

Incyte Market Cap: 17.5 B USD

The current market cap of Incyte is 17.5 B USD.

Incyte Stock Price: 86.16 USD

The current stock price of Incyte is 86.16 USD.

Incyte ISIN: US45337C1027

The ISIN (International Securities Identification Number) of Incyte is US45337C1027.

Incyte Ticker Symbol: INCY

The ticker symbol of Incyte is INCY.

Incyte Address

The address of the Incyte HQ is 1801 Augustine Cut-Off, 19803 Wilmington, DE, USA.